BioCentury
ARTICLE | Top Story

Opdivo, Cometriq meet in Phase III mRCC trials

July 21, 2015 12:46 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and Exelixis Inc. (NASDAQ:EXEL) each reported results Monday from Phase III trials of therapies to treat metastatic renal cell carcinoma (RCC).

BMS stopped the Phase III CheckMate -025 trial of Opdivo nivolumab in patients with advanced or metastatic RCC after an independent data monitoring committee concluded Opdivo met the primary endpoint of improving overall survival (OS) compared to Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN). Patients had received one or two prior anti-angiogenic therapies. The company did not release detailed data; BMS spokesperson Carrie Fernandez declined to provide a regulatory submission timeline for the drug in RCC. ...